A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression o...A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.展开更多
Mogamulizumab是一种定向作用于CC趋化因子受体4的重组人源化单克隆抗体,用于治疗至少接受过1次预先全身治疗后的复发性或难治性蕈样肉芽肿或Sézary综合征的成年患者。与伏立诺他相比,本品可延长患者无进展生存期。本品于2018年8...Mogamulizumab是一种定向作用于CC趋化因子受体4的重组人源化单克隆抗体,用于治疗至少接受过1次预先全身治疗后的复发性或难治性蕈样肉芽肿或Sézary综合征的成年患者。与伏立诺他相比,本品可延长患者无进展生存期。本品于2018年8月获美国食品药品监督管理局(Food and Drug Administration,FDA)批准在美国上市。本文就其作用机制、药代动力学、临床评价、不良反应、用法用量等进行综述,旨在为临床用药提供参考。展开更多
文摘A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.
文摘Mogamulizumab是一种定向作用于CC趋化因子受体4的重组人源化单克隆抗体,用于治疗至少接受过1次预先全身治疗后的复发性或难治性蕈样肉芽肿或Sézary综合征的成年患者。与伏立诺他相比,本品可延长患者无进展生存期。本品于2018年8月获美国食品药品监督管理局(Food and Drug Administration,FDA)批准在美国上市。本文就其作用机制、药代动力学、临床评价、不良反应、用法用量等进行综述,旨在为临床用药提供参考。
